Concerning overall survival, the combined hazard ratio 1.31 (95%CI: 1.06–1.62) in the fixed-effect model corroborates the results of the one-stage meta-analysis, affirming an association between continuous Lev use and enhanced survival time in IDH wild-type glioblastoma.The assessment indicated no substantial heterogeneity (I2 = 31%, p = 0.23), which makes the results from the fixed-effect model appropriate. This evidence concerns the gene IDH1 and glioblastoma.